GlassScriptPhysician profile
Dennis A Robinson
NPI 1114017449
$12,133.43
in general payments reported to CMS, 2019-2025
41 companies · $2,907 in 2025
The $2,907 reported for 2025 was more than what 75% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $580 · 2020: $1,259 · 2021: $1,186 · 2022: $1,892 · 2023: $2,114 · 2024: $2,196 · 2025: $2,907.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,113 · Consulting Fee: $69.63 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,112.83 |
| Consulting Fee | $69.63 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,275.49 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Octapharma USA, INC. | $1,224.75 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,030.69 | 2020-2025 | Cuvitru, Glassia, Takhzyro |
| Regeneron Healthcare Solutions, INC. | $1,007.73 | 2019-2025 | Dupixent |
| Biocryst US Sales Co., LLC | $825.43 | 2021-2025 | Orladeyo |
| Astrazeneca Pharmaceuticals LP | $822.64 | 2019-2025 | Airsupra, Tezspire, Bevespi Aerosphere |
| Pfizer INC. | $720.96 | 2019-2025 | |
| Grifols USA, LLC | $688.07 | 2019-2025 | Xembify, Prolastin-C Liquid |
| Genzyme Corporation | $531.37 | 2020-2025 | |
| Csl Behring | $513.50 | 2019-2025 | Hizentra, Andembry, Haegarda |
| Amgen INC. | $478.96 | 2022-2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $373.30 | 2020-2025 | |
| Leo Pharma INC. | $349.70 | 2022-2025 | Adbry, Anzupgo |
| Abbvie INC. | $264.06 | 2021-2024 | Rinvoq |
| Aimmune Therapeutics, INC. | $211.00 | 2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dennis Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.